Pseudomonas aeruginosa
From IDWiki
Pseudomonas aeruginosa /
Revision as of 19:08, 20 August 2020 by Aidan (talk | contribs) (Text replacement - "\[\[Oxidase test::(.*?)-(.*?)\]\]" to "$1 Oxidase::$2")
Background
Microbiology
- Oxidase-positive]], non-fermenting Gram [[Oxidase::negative"Gram [[Oxidase::negative" is not in the list (Gram-positive, Gram-negative, acid-fast, partially acid-fast, Gram-variable) of allowed values for the "Stain" property. bacillus
Mechanisms of Resistance
- Broad intrinsic and acquired antibiotic resistance
- Membrane impermeability
- Decreased or absent OprD porin: resistance to carbapenems (imipenem and meropenem)
- Membrane changes: resistance to polymixins (colistin)
- Reduced aminoglycoside transport: resistance to aminoglycosides
- Efflux pumps
- MexAB-OprM: resistance to fluoroquinolones and all β-lactams except imipenem
- MexCD-OprJ: resistance to fluoroquinolones and most β-lactams (cefoperazone, cefpirome, cefepime, meropenem) but not imipenem
- MexEF-OprN: resistance to fluoroquinolones and all β-lactams
- MexXY-OprM: resistance to fluoroquinolones, most β-lactams (but not imipenem), and aminoglycosides
- β-lactamases
- Derepressed AmpC β-lactamase: resistance to penicillins and cephalosporins (except ceftolozane)
- Acquired carbapenemases such as NDM-1: resistance to essentially all β-lactam antibiotics
- Aminoglycoside-modifying enzymes: resistance to aminoglycosides
- Target site mutations
- Topoisomerase II (gyrA) or IV (parC) point mutations: resistance to fluoroquinolones
Epidemiology
- Loves moist and wet environments
- Causes healthcare-associated infections
- UTI, SSI, bacteremia, HAP, VAP
- Especially common in cystic fibrosis
Treatment
- Refer to antipseudomonal antibiotics for specific treatment options
- Double coverage (ß-lactam + non-ß-lactam) in cases of severe infection in order to ensure activity against the infection